Bacteriophage therapy uses viruses known as bacteriophages to infect and destroy specific bacterial pathogens, offering a targeted approach that reduces harm to beneficial microbiota and minimizes antibiotic resistance issues. One significant application is in treating antibiotic-resistant infections, such as those caused by MRSA (methicillin-resistant Staphylococcus aureus). Phages can specifically target and kill these resistant bacteria, providing a potential solution when traditional antibiotics fail. This application is particularly valuable in hospital settings, where resistant infections pose significant health risks.
Global Bacteriophages Therapy Market is valued at 39.80 million in 2021 and is expected to reach USD 64.40 million by 2029, with a growing CAGR of 6.20% during the forecast period 2022 to 2029.
To know more, visit https://www.databridgemarketresearch.com/ar/reports/global-bacteriophages-therapy-market
Below are the Top Bacteriophages Therapy Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Microgen
|
Microgen is a biotechnology company specializing in bacteriophage research and development. They focus on creating phage-based therapies to combat antibiotic-resistant bacterial infections. Microgen’s products target a range of bacterial pathogens, and they aim to provide innovative solutions for both human health and agricultural applications.
|
|
Europe
|
In October 2018, Microgen announced that Russian Bacteriophages are used in prevention of emergency infections. The company further added that over 3,000 products have been delivered to Kuban. This has helped the company to earn more revenue
|
|
2.
|
Adaptive Phage Therapeutics
|
Adaptive Phage Therapeutics is a biopharmaceutical company dedicated to developing precision-targeted bacteriophage therapies. Their approach involves an adaptive platform that matches bacteriophages to specific bacterial infections, addressing antibiotic resistance. They collaborate with various research institutions and have ongoing clinical trials to bring phage therapy to the forefront of infectious disease treatment.
|
|
North America, Asia, and Europe
|
In June 2021, Adaptive Phage Therapeutics announced the initiation of Phase 1/2 study of bacteriophage therapy (Phage Bank) to evaluate the safety, tolerability and efficacy of targeted, personalized, bacteriophage (“phage”) treatments in patients with urinary tract infection (UTI). This has helped the company to develop novel treatment for multi-drug resistant bacterial infections.
|
|
3.
|
Phagelux, Inc.
|
Phagelux, Inc. is a global biotechnology company that develops bacteriophage-based solutions for health, agriculture, and food safety. They leverage phage technology to address bacterial issues in various industries, including human therapeutics and crop protection. Phagelux’s innovations aim to provide sustainable and effective alternatives to traditional antibiotics and pesticides.
|
|
North America, Asia-Pacific, and Europe
|
In April 2020, Phagelux,Inc announced that the company has entered into multiple commercial collaborations such as European sales, marketing and product development collaboration with DCM for its AgriPhage line of biopesticides, among others. This has helped the company to fully explore and develop next generation bacteriophages.
|
|
4.
|
LOCUS BIOSCIENCES, INC.
|
LOCUS BIOSCIENCES, INC. is a biotechnology firm that combines CRISPR-Cas3 technology with bacteriophages to create powerful antibacterial agents. Their proprietary platform targets specific bacterial strains, providing precision therapy for antibiotic-resistant infections. LOCUS BIOSCIENCES is focused on advancing their products through clinical trials to offer new treatment options in the medical field.
|
|
North America
|
In March 2021, LOCUS BIOSCIENCES, INC. announced the results of phase 1b clinical trial of CRISPR-Cas3-enhanced bacteriophages designed for the treatment of urinary tract infections caused by Escherichia coli. This has helped the company to offer ultimate treatment for the disease and hence earn more revenue.
|
|
5.
|
ATCC
|
ATCC (American Type Culture Collection) is a nonprofit organization that supplies biological materials and standards, including bacteriophages, for scientific research. While not a commercial developer of phage therapies, ATCC supports the bacteriophage therapy market by providing critical resources for researchers and companies developing phage-based treatments. Their extensive catalog of phages and bacterial strains is vital for advancing bacteriophage research and application.
|
|
North America
|
In June 2016, ATTC announced that the company has received “Distinguished Lifetime Achievement Award” from Society of In-Vitro Biology. This has motivated the company and boosts the enthusiasm of employees.
|
Conclusion
The bacteriophage therapy market is witnessing significant advancements through the efforts of pioneering companies such as Microgen, Adaptive Phage Therapeutics, Phagelux, Inc., LOCUS BIOSCIENCES, INC., and ATCC. These organizations are driving innovation by developing targeted phage-based solutions to combat antibiotic-resistant bacterial infections. Their diverse approaches range from precision-targeted therapies and CRISPR-enhanced phages to supporting research with essential biological materials. Collectively, these companies are shaping the future of bacteriophage therapy, offering promising alternatives to traditional antibiotics and addressing critical global health challenges.
